Erythropoietin (rHuEPO) & Erythropoiesis-Stimulating Agents (Darbepoetin, CERA, HIF Stabilisers)
Erythropoietin (rHuEPO) & Erythropoiesis-Stimulating Agents (Darbepoetin, CERA, HIF Stabilisers) is classified under Group B (Pharmacological & Prohibited Performance-Enhancing Substances). It is NOT recommended as an athletic performance aid. This monograph provides objective clinical pharmacology, toxicology, Indian statutory regulation, and WADA anti-doping education only—it never provides doping cycles, stacking regimens, or testing-evasion instructions. Any legitimate therapeutic use requires specialist medical diagnosis and supervision.
1. Generic or Accepted Substance Name & Classifications
Accepted Name: Erythropoietin (rHuEPO) & Erythropoiesis-Stimulating Agents (Darbepoetin, CERA, HIF Stabilisers)
Common Names, Synonyms & Classifications: Epoetin Alfa IP (rHuEPO); Epoetin Beta; Darbepoetin Alfa; Methoxy Polyethylene Glycol-Epoetin Beta (CERA); Roxadustat; Daprodustat; Desidustat
Section Classification: Group B — Pharmacological & Prohibited Performance-Enhancing Substances (PERF-B13)
2. Pharmacological Class
Recombinant Erythropoietic Glycoprotein Hormones & Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors (HIF-PHIs)
3. Mechanism of Action
rHuEPO and Darbepoetin bind the Erythropoietin Receptor (EPOR) on bone-marrow erythroid progenitor cells (CFU-E), activating the JAK2/STAT5 signalling pathway to prevent apoptosis and stimulate reticulocyte maturation and red blood cell (RBC) production. Oral HIF-PHIs (e.g., Desidustat, Roxadustat) inhibit prolyl hydroxylase domain (PHD) enzymes, stabilising HIF-1alpha/HIF-2alpha to stimulate endogenous renal/hepatic EPO transcription.
4. Proposed Performance or Endurance Effects (Pharmacological Effect vs Proven Athletic Outcome)
Pharmacological Effect: Increases red blood cell mass, haematocrit, and arterial oxygen content (CaO₂). Anti-Doping & Clinical Reality: One of the most dangerous prohibited doping classes in endurance sports (cycling, marathon, race walking, cross-country skiing). Raising haematocrit above physiological levels (>50%) exponentially increases whole-blood viscosity—especially when combined with exercise-induced dehydration—precipitating fatal nocturnal bradycardic thrombosis, pulmonary embolism, stroke, and myocardial infarction.
5. Quality of Scientific Evidence
Evidence Assessment: PROHIBITED PHARMACOLOGICAL DOPING CLASS (WADA S2.1) — High Lethal Thromboembolic Risk When Misused in Non-Anaemic Athletes
6. Approved Medical Uses (Where Applicable)
Erythropoietin Alfa IP and Darbepoetin Alfa are NLEM 2022 / IP 2022 specialist prescription medicines strictly indicated for anaemia of Chronic Kidney Disease (CKD), myelosuppressive cancer chemotherapy, and zidovudine-treated HIV patients (with a strict clinical haemoglobin target ceiling of 10–11.5 g/dL to prevent cardiovascular mortality).
7. Sports-Related Uses, Misuse Patterns & Contamination Risks
Illicit subcutaneous/intravenous micro-dosing of rHuEPO/CERA or oral abuse of HIF stabilisers (Desidustat, Roxadustat) in endurance sports. Detectable via WADA Athlete Biological Passport (ABP haematological module: haemoglobin, reticulocyte %, OFF-hr score) and Isoelectric Focusing (IEF) / SAR-PAGE electrophoresis.
8. Adverse Effects & Serious Safety Risks
Hyperviscosity syndrome, deep vein thrombosis (DVT), pulmonary embolism, cerebral venous sinus thrombosis, ischaemic stroke, myocardial infarction, severe systemic hypertension and hypertensive encephalopathy/seizures, and Pure Red Cell Aplasia (PRCA) mediated by neutralising anti-EPO antibodies.
9. Contraindications & Precautions
Uncontrolled hypertension, history of thromboembolism, polycythaemia, normal/elevated haemoglobin (>12 g/dL), and non-medical athletic use.
10. Drug Interactions
Additive thrombotic risk with erythropoietic co-factors, oral contraceptives, or dehydration; ACE inhibitors/ARBs may slightly blunt erythropoietic response in CKD patients.
11. Clinical & Laboratory Monitoring Considerations
In clinical CKD/oncology care: Haemoglobin/haematocrit every 1–2 weeks during initiation (reduce or withhold dose if Hb rises >1 g/dL in 2 weeks or exceeds 11.5 g/dL), blood pressure, serum ferritin, and transferrin saturation.
12. Dependence, Misuse or Withdrawal Concerns
No neurochemical addiction; discontinuation after illicit doping causes compensatory suppression of endogenous erythropoietin and rebound reticulocytopenia/anaemia.
13. Regulatory & Legal Status in India (CDSCO / Drugs Rules / NDPS / FSSAI)
Schedule H prescription biological drugs under the Drugs and Cosmetics Act, 1940 and IP 2022 ([s3-bklg-19]); cold-chain storage at 2°C–8°C is mandatory (do not freeze or shake).
14. Official WADA Prohibited-List Status
PROHIBITED AT ALL TIMES (In-Competition and Out-of-Competition) under WADA Prohibited List Category S2.1 (Erythropoietins and Agents Affecting Erythropoiesis, including EPO-receptor agonists and HIF-activating agents) and M1 (Manipulation of Blood and Blood Components).
15. Authoritative Source References & Date of Last Verification
Date of Last Verification: 11 November 2026